Regenerative Medicine Therapies for Targeting Neuroinflammation After Stroke

References 180

1. 1.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

2. 2.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

3. 3.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

4. 4.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

5. 5.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

6. 6.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

7. 7.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

8. 8.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

9. 9.

   This reference’s wording can’t be shown under the paper’s licence.

   Not in our library

10. 10.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

11. 11.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

12. 12.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

13. 13.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

14. 14.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

15. 15.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

16. 16.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

17. 17.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

18. 18.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

19. 19.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

20. 20.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

21. 21.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

22. 22.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

23. 23.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

24. 24.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

25. 25.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

26. 26.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

27. 27.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

28. 28.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

29. 29.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

30. 30.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

31. 31.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

32. 32.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

33. 33.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

34. 34.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

35. 35.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

36. 36.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

37. 37.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

38. 38.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

39. 39.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

40. 40.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

41. 41.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

42. 42.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

43. 43.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

44. 44.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

45. 45.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

46. 46.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

47. 47.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

48. 48.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

49. 49.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

50. 50.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

51. 51.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

52. 52.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

53. 53.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

54. 54.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

55. 55.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

56. 56.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

57. 57.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

58. 58.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

59. 59.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

60. 60.
    Bipolar/rod-shaped microglia are proliferating microglia with distinct M1/M2 phenotypes · 2014

    No notice
61. 61.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

62. 62.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

63. 63.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

64. 64.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

65. 65.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

66. 66.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

67. 67.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

68. 68.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

69. 69.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

70. 70.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

71. 71.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

72. 72.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

73. 73.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

74. 74.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

75. 75.
    Attenuation of acute stroke injury in rat brain by minocycline promotes blood–brain barrier remodeling and alternative microglia/macrophage activation during recovery · 2015

    No notice
76. 76.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

77. 77.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

78. 78.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

79. 79.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

80. 80.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

81. 81.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

82. 82.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

83. 83.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

84. 84.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

85. 85.
    Inflammatory mechanisms in ischemic stroke: therapeutic approaches · 2009

    No notice
86. 86.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

87. 87.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

88. 88.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

89. 89.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

90. 90.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

91. 91.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

92. 92.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

93. 93.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

94. 94.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

95. 95.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

96. 96.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

97. 97.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

98. 98.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

99. 99.

    This reference’s wording can’t be shown under the paper’s licence.

    Not in our library

100. 100.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

101. 101.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

102. 102.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

103. 103.
     Implications of MMP9 for Blood Brain Barrier Disruption and Hemorrhagic Transformation Following Ischemic Stroke · 2016

     No notice
104. 104.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

105. 105.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

106. 106.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

107. 107.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

108. 108.
     The blood–brain barrier after stroke: Structural studies and the role of transcytotic vesicles · 2016

     No notice
109. 109.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

110. 110.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

111. 111.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

112. 112.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

113. 113.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

114. 114.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

115. 115.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

116. 116.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

117. 117.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

118. 118.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

119. 119.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

120. 120.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

121. 121.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

122. 122.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

123. 123.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

124. 124.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

125. 125.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

126. 126.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

127. 127.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

128. 128.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

129. 129.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

130. 130.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

131. 131.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

132. 132.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

133. 133.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

134. 134.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

135. 135.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

136. 136.
     Interleukin-1 primes human mesenchymal stem cells towards an anti-inflammatory and pro-trophic phenotype in vitro · 2017

     No notice
137. 137.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

138. 138.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

139. 139.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

140. 140.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

141. 141.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

142. 142.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

143. 143.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

144. 144.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

145. 145.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

146. 146.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

147. 147.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

148. 148.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

149. 149.
     Anti-Inflammatory Targets for the Treatment of Reperfusion Injury in Stroke · 2017

     No notice
150. 150.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

151. 151.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

152. 152.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

153. 153.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

154. 154.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

155. 155.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

156. 156.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

157. 157.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

158. 158.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

159. 159.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

160. 160.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

161. 161.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

162. 162.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

163. 163.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

164. 164.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

165. 165.
     An Inflammation-Centric View of Neurological Disease: Beyond the Neuron · 2018

     Corrected
166. 166.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

167. 167.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

168. 168.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

169. 169.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

170. 170.
     Memantine loaded PLGA PEGylated nanoparticles for Alzheimer’s disease: in vitro and in vivo characterization · 2018

     No notice
171. 171.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

172. 172.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

173. 173.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

174. 174.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

175. 175.
     The therapeutic potential of the mesenchymal stem cell secretome in ischaemic stroke · 2018

     No notice
176. 176.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

177. 177.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

178. 178.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

179. 179.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

180. 180.

     This reference’s wording can’t be shown under the paper’s licence.

     Not in our library

Cited by papers we hold 2

• Neuroinflammation in Cerebral Ischemia and Ischemia/Reperfusion Injuries: From Pathophysiology to Therapeutic Strategies · 2021
  No notice
• Key for crossing the BBB with nanoparticles: the rational design · 2020
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.